Palatin's Cardiac Drug Meets End Point in Phase I Heart Failure Trial
Posted on: Tuesday, 11 March 2008, 12:00 CDT
Palatin Technologies has completed the Phase I clinical trial of PL-3994, a novel, long-acting natriuretic peptide receptor A agonist, under development for treatment of acute decompensated congestive heart failure or CHF.
Dosing concluded with the successful achievement of the primary endpoint of the study, a prespecified reduction in systemic blood pressure. No volunteer experienced a serious or severe adverse event. Elevations in plasma cyclic guanosine monophosphate levels (cGMP), increased diuresis (urine excretion) and increased natriuresis (sodium excretion) were all observed for several hours after single sub- cutaneous doses. Data analysis is ongoing and will be submitted for presentation when the analysis is complete.
The Phase I trial was a randomized, double-blind, placebo- controlled, single ascending dose study in 26 healthy volunteers who received the medication or placebo subcutaneously. The evaluations included safety, tolerability, pharmacokinetics and several pharmacodynamic endpoints, including levels of cGMP, a natural messenger nucleotide.
Palatin is currently developing PL-3994 for the treatment of acute decompensated CHF and plans to initiate a Phase IIa study in these patients later this year. Future plans include the development of PL-3994 for long term administration in patients with chronic CHF. In addition, Palatin plans to develop PL-3994 for the emergency treatment of severe acute systemic hypertension. A Phase IIa study in hypertensive subjects is also planned to start later this year."
Source: Datamonitor
Related Articles
- Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
- QuatRx Pharmaceuticals Announces Presentation of Further Data From Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
- MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
- Cardiome Initiates Phase I Study of Cardiovascular Drug
- Xanthus Initiates a Phase 1 Study of Clomet for Treatment of Solid Tumors
- PRP Announces Initiation of a Phase I Study of a New Potential Treatment for Pulmonary Arterial Hypertension
- Metabasis Comments on Positive 48 Week HBV Data From Pradefovir Mesylate Phase 2 Study Reported By Valeant Pharmaceuticals
- Valeant Pharmaceuticals Reports Positive Data From Pradefovir Mesylate Phase 2 Study
- Xanthus Initiates a Phase 2 Study Of Xanafide in Combination With Ara-C for Treatment Of Secondary AML
- Metabasis Comments on Positive Data Reported By Valeant Pharmaceuticals From Pradefovir Mesylate Phase 2 Study
 |
 |
User Comments (0)
RSS Feeds